Product Name: GSK3a (16-24) pT19+pS21
Product Number: PE-04AMR99
| Size: | 200 µg | Price: | 68.00 | |
| 1 mg | $US | 136.00 | ||
| 5 mg | 297.00 |
Peptide Name: GSK3a (16-24) pT19+pS21
Product Use: Services as a blocking peptide for use with the GSK3a-pT19+pS21 rabbit polyclonal antibody (Cat. No.: AB-PK648) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located near the N-terminus of the protein. Phosphorylation inhibits phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RAR-pT-S-pS-FAE
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Product Use: Services as a blocking peptide for use with the GSK3a-pT19+pS21 rabbit polyclonal antibody (Cat. No.: AB-PK648) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located near the N-terminus of the protein. Phosphorylation inhibits phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RAR-pT-S-pS-FAE
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1358.27 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: GSK3a - pT19+pS21 phosphosite-specific antibody (Cat. No.: AB-PK648)
Peptide Molecular Mass Calculated: 1358.27 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: GSK3a - pT19+pS21 phosphosite-specific antibody (Cat. No.: AB-PK648)
Scientific Background: GSK3a is a protein-serine/threonine kinase of the CMGC group and GSK family. It is highly active following tyrosine phosphorylation within its activation T loop. Phosphorylation at Y279 increases phosphotransferase activity and promotes nuclear localization. Phosphorylation at S21 inhibits phosphotransferase activity. Through direct phosphorylation, it can inactivate glycogen synthase (for insulin regulation), CTNNB1/beta-catenin, APC, and AXIN1. GSK3 has been proposed as a tumour suppressor protein (TSP), since with loss of GSK3 there is an increase in WNT signalling, with a beta-catenin stabilization, leading to tumourigenesis. GSK3 has also been proposed to act as an oncoprotein (OP), as acute leukemia required GSK3 for cell proliferation. In most human cancers, it is up-regulated in expression about 1.6-times the rate observed for most protein kinases.
© Kinexus Bioinformatics Corporation 2017